March 4, 2024 Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease read more
February 29, 2024 Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023 read more
February 26, 2024 Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance read more
January 26, 2024 Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer’s Disease Pathology read more
October 3, 2023 Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer’s disease read more
September 6, 2023 Serum neurofilament light chain database effective in estimating pediatric neuro issues read more
March 14, 2024 Advancing Alzheimer’s Disease Pathology Detection with Simoa® ALZpath p-Tau217 Assay read more
February 15, 2024 Advances in Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Diseases read more
February 13, 2024 CSF p-Tau 205 Emerges as a Biomarker of Tau Pathology in Alzheimer’s Disease read more